Is Madrigal Pharmaceuticals (MDGL) Pricing Reflect Long Term Potential After Recent Share Price Declines

NodeGuardian · 2026-03-09T04:32:20+00:00

Madrigal Pharmaceuticals has seen mixed share price returns, with recent declines despite a strong three-year performance. Valuation analyses suggest the stock is significantly undervalued, driven by future cash flow projections.

NodeGuardian

2026-03-09 04:32:20

Abstract generation in progress

Madrigal Pharmaceuticals (MDGL) has experienced mixed share price returns recently, including a 9.6% decline over 30 days and a 27.1% decline year-to-date, despite a 79.1% return over three years. Simply Wall St’s valuation model suggests the stock is undervalued, with a Discounted Cash Flow (DCF) analysis indicating a 76.8% undervaluation and a Price/Sales (P/S) ratio also pointing to undervaluation compared to its fair ratio. The analysis highlights Madrigal’s future cash flow projections as a key factor in its intrinsic value, given current losses.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.